Press Releases

Press Releases

Date Title & Summary Additional Formats
09/03/19
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan , which will be
08/21/19
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
SAN DIEGO --(BUSINESS WIRE)--Aug. 21, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak ® antiviral program have
08/08/19
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
SAN DIEGO , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate activities
08/07/19
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at the
07/29/19
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Rezafungin met its objectives for efficacy, safety and tolerability Global Phase 3 ReSTORE trial
06/05/19
Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019
Company secures two oral and four poster presentations Presentations include new data highlighting the antiviral effect and immune system engagement of CB-012 for the prevention and treatment of flu SAN DIEGO --(BUSINESS WIRE)--Jun. 5, 2019-- Cidara Therapeutics, Inc.
05/09/19
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
SAN DIEGO , May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2019 and provided an update on its corporate activities
04/16/19
Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019
Data featured in three oral and five poster presentations reinforce potential of novel antifungal for the treatment and prevention of serious invasive infections SAN DIEGO --(BUSINESS WIRE)--Apr. 16, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel
04/15/19
Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program
CB-012 demonstrates potent antiviral activity against influenza A and B viruses Cidara presenting preclinical results today at ECCMID 2019 SAN DIEGO --(BUSINESS WIRE)--Apr. 15, 2019-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
04/03/19
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
SAN DIEGO , April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18